APLIF Stock Chart & Stats
$0.01
>-$0.01(-1.27%)
At close: 4:00 PM EDT
$0.01
>-$0.01(-1.27%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.03
Previous CloseN/A
Volume80.20K
Average Volume (3M)43.77K
Market Cap
$1.43M
Enterprise Value$15.17
Total Cash (Recent Filing)$138.68K
Total Debt (Recent Filing)$13.33M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding132,366,120
10 Day Avg. Volume6,020
30 Day Avg. Volume43,769
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.11
Price to Sales (P/S)7.60
P/FCF Ratio-1.34
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe reported 249% growth rate indicates meaningful expansion from the prior period. Although the revenue base remains very small, continued product or partnership activity could support operating scale if growth becomes repeatable.
High Gross MarginA gross margin near 97% suggests that successfully commercialized products could retain substantial revenue after direct costs. This provides potential operating leverage, though sustained profitability still depends on controlling development and corporate expenses.
Infectious Disease PipelineThe infectious-disease focus targets persistent healthcare needs and gives the company a defined therapeutic strategy. Advancing candidates toward approval, licensing, or partnerships could create longer-term commercialization routes.
Bears Say
Negative Equity And LeverageNegative equity and debt that is large relative to assets materially weaken financial flexibility. The structure increases refinancing and dilution risk, potentially limiting the company’s ability to fund clinical development without external capital.
Persistent Cash BurnNegative operating and free cash flow show that the business is not self-funding. Continued cash consumption creates recurring financing needs and could force additional equity issuance or debt funding while development programs advance.
Limited Scale And LossesThe very small revenue base and sustained operating and net losses indicate that commercial scale has not yet been established. Revenue volatility and the lack of a sustained path to breakeven constrain visibility into future profitability.
Appili Therapeutics Inc Class A News
APLIF FAQ
What was Appili Therapeutics Inc Class A’s price range in the past 12 months?
Appili Therapeutics Inc Class A lowest stock price was <$0.01 and its highest was $0.03 in the past 12 months.
What is Appili Therapeutics Inc Class A’s market cap?
Appili Therapeutics Inc Class A’s market cap is $1.43M.
When is Appili Therapeutics Inc Class A’s upcoming earnings report date?
Appili Therapeutics Inc Class A’s upcoming earnings report date is Nov 12, 2026 which is in 76 days.
How were Appili Therapeutics Inc Class A’s earnings last quarter?
Appili Therapeutics Inc Class A released its earnings results on Aug 14, 2026. The company reported -$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Appili Therapeutics Inc Class A overvalued?
According to Wall Street analysts Appili Therapeutics Inc Class A’s price is currently Overvalued.
Does Appili Therapeutics Inc Class A pay dividends?
Appili Therapeutics Inc Class A does not currently pay dividends.
What is Appili Therapeutics Inc Class A’s EPS estimate?
Appili Therapeutics Inc Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Appili Therapeutics Inc Class A have?
Appili Therapeutics Inc Class A has 132,366,120 shares outstanding.
What happened to Appili Therapeutics Inc Class A’s price movement after its last earnings report?
Appili Therapeutics Inc Class A reported an EPS of -$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Appili Therapeutics Inc Class A?
Currently, no hedge funds are holding shares in APLIF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Appili Therapeutics Inc Class A
Appili Therapeutics Inc., a Canadian biopharmaceutical firm headquartered in Halifax and founded in 2015, specializes in sourcing and advancing innovative treatments to address critical gaps in infectious disease medicine. The company's diverse pipeline includes Favipiravir, utilized for pandemic influenza and COVID-19, and the clinical-stage antifungal ATI-2307, which targets cryptococcal meningitis and invasive candidiasis. Other programs feature ATI-1503, a new class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral metronidazole suspension; ATI-1801, a novel topical formulation of paromomycin for treating cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine designed for Francisella tularensis. Additionally, Appili maintains a strategic collaboration with AiPharma Global Holdings LLC for the ongoing development of Avigan/Reeqonus (favipiravir).